Eli Lilly and Company reported positive topline results from its Phase 3 BRUIN CLL-322 trial for Jaypirca (pirtobrutinib). The study evaluated Jaypirca in combination with venetoclax and rituximab for patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).
The trial met its primary endpoint by demonstrating a statistically significant and clinically meaningful improvement in progression-free survival. These results remained consistent across key patient subgroups, regardless of prior treatment with a BTK inhibitor.
Eli Lilly plans to submit the data to regulatory authorities for a potential label expansion later this year. The company will present detailed findings at an upcoming medical conference. The overall safety profile proved consistent with the known profiles of the individual medicines.